SPT Labtech has entered a strategic collaboration with Illumina to develop a novel automated sample preparation platform designed to streamline and standardize genomics workflows across decentralized healthcare environments.
The companies will develop an automated platform that supports laboratories using Illumina’s MiSeq i100 benchtop sequencing system. The solution aims to deliver standardized, automated workflows that enable laboratories to generate rapid, high-quality genomic insights closer to the point of care.
The collaboration targets improved patient care in oncology by expanding access to high-quality genomic characterization of disease. By bringing advanced automation to laboratories of all sizes, the companies aim to accelerate the delivery of actionable insights from sample to result.
The new platform builds on the existing partnership between SPT Labtech and Illumina, including development of automated library preparation methods on SPT Labtech’s firefly® platform. The companies now seek to extend automation, precision, and reproducibility to decentralized laboratories, providing capabilities typically associated with large core facilities.
Working in analytical science?
Register for a FREE Separation Science account to subscribe to the Separation Science Newsletter.
“This next phase of collaboration with Illumina reflects our shared focus on enabling efficient and accessible genomics workflows, further expanding SPT Labtech’s presence in the clinical genomics market," remarks Rob Walton, Chief Executive Officer at SPT Labtech. "With the rapid global adoption of Illumina’s MiSeq i100 platform and the recent shipment of its 1,000th system, there is a growing demand from laboratories seeking to perform their sequencing operations in-house, thereby maximizing control and reducing turnaround times. By combining our expertise in automation and sequencing, we are well positioned to help laboratories adopt advanced genomics workflows within decentralized healthcare settings.”
“Labs around the world rely on Illumina for high-quality, reliable insights and end-to-end workflows that make it easier for them to unlock crucial genomic insights faster," adds Todd Christian, senior vice president of Services, Arrays, and Genomic Access at Illumina. "This collaboration builds on that history and doubles down on our commitment to expand access to next-generation sequencing for labs of all sizes, ultimately enabling researchers and clinicians to drive breakthroughs that matter for the patients they serve.”
This article is a rework of a press release issued by SPT Labtech.
